Clinical Trial Update: EIM Via the Myolex mScan as an ALS Biomarker

View source ↗

Summary

An ALS biomarker study is evaluating the Myolex mScan in a clinical trial sponsored by Beth Israel Deaconess Medical Center. The study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Amyotrophic Lateral Sclerosis | Status: RECRUITING